Log In
Print
BCIQ
Print
Print this Print this
 

ALS-2200, VX-135

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionNucleotide HCV NS5B polymerase inhibitor
Molecular Target HCV NS5B polymerase
Mechanism of ActionHCV non-structural protein 5B inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV infection; Treat HCV genotype 1 infection; Treat HCV infection; Treat non-cirrhotic, treatment-naïve patients with chronic HCV genotype 1 infection
Regulatory Designation

Partner

Vertex Pharmaceuticals Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$3,310.0M

$1,810.0M

$1,500.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today